

Follicle diameter study: timing of human chorionic gonadotropin administration according to predetermined criteria of follicular size

Submission date 08/02/2007	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 08/02/2007	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 15/08/2011	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

<http://www.studies-obsgyn.nl>

Contact information

Type(s)

Scientific

Contact name

Dr M H Mochtar

Contact details

Academic Medical Centre
Centre for Reproductive Medicine
Amsterdam
Netherlands
1100 DE
M.H.Mochtar@amc.uva.nl

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Study objectives

To assess whether delayed administration of human Chorionic Gonadotropin (hCG) for controlled ovarian hyperstimulation for In Vitro Fertilisation (IVF) and embryo transfer leads to an increased advanced stage of endometrium, and prolonged exposure to high levels of estradiol which may result in a lower pregnancy rate.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approval received from the Ethics Board of the Academic Medical Center, Amsterdam, on the 20th July 2005 (ref: MEC 05/161 #05.17.1237).

Study design

Randomised, active-controlled, parallel group, multicentre trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

In Vitro Fertilisation (IVF), timing of human Chorionic Gonadotropin (hCG) administration, follicle size

Interventions

hCG administration for follicular maturation when the dominant follicle measures 18 mm compared to hCG administration for follicular maturation when the dominant follicle measures 22 mm.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Human Chorionic Gonadotropin (hCG)

Primary outcome measure

Ongoing pregnancy rate, defined as a positive foetal heartbeat by ultrasound at ten weeks after oocyte retrieval.

Secondary outcome measures

1. Endometrium thickness, three-layer aspect
2. Total days of controlled hyper stimulation
3. Total amount of recombinant FSH (rFSH) used
4. Total number of retrieved oocytes
5. Number of score one oocytes (IVF only)
6. Number of metaphase two oocytes (ICSI only)
7. Fertilisation rate
8. Number and quality of embryos
9. Pronuclear morphology
10. Presence of early cleavage
11. Daily morphological quality of embryos until transfer
12. Number of embryos suited for cryo-preservation
13. Ovarian Hyper-Stimulation Syndrome (OHSS)/discontinuation due a high risk of OHSS
14. Biochemical and clinical pregnancy rates, defined as a increase in serum hCG or a positive pregnancy test and positive heartbeat by ultrasound at seven weeks after oocyte retrieval, respectively

Overall study start date

01/04/2006

Completion date

01/04/2008

Eligibility

Key inclusion criteria

1. Age between 18 and 42 and 11 months
2. Valid indication for IVF or Intra-Cytoplasmic Sperm Injection (ICSI)
3. Undergoing their first or second IVF/ICSI attempt
4. Normal Follicle-Stimulating Hormone (FSH) levels (less than 15)
5. Antral follicle count more than five for women between 40 and 43

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Not Specified

Target number of participants

400

Key exclusion criteria

1. Endocrinopathological disease as: Poly-Cystic Ovarian Syndrome (PCOS), cushing syndrome, adrenal hyperplasia, hyperprolactinaemia, acromegaly, hypothalamic amenorrhoea, hypothyroidy, diabetes mellitus type one
2. Premature ovarian failure defined as a FSH level on cycle-day three of more than or equal to 15 IU at the age of 40
3. Low responders defined as follicle growth of less than three follicles during controlled ovarian hyperstimulation (including the dominant follicle)

Date of first enrolment

01/04/2006

Date of final enrolment

01/04/2008

Locations**Countries of recruitment**

Netherlands

Study participating centre

Academic Medical Centre

Amsterdam

Netherlands

1100 DE

Sponsor information**Organisation**

Academic Medical Centre (AMC) (The Netherlands)

Sponsor details

Center For Reproductive Medicine

P.O. Box 22660

Amsterdam
Netherlands
1100 DD

Sponsor type

Hospital/treatment centre

Website

<http://www.amc.uva.nl/#http://www.amc.uva.nl/>

ROR

<https://ror.org/03t4gr691>

Funder(s)

Funder type

Industry

Funder Name

Organon (The Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2011		Yes	No